Lates News

Prospects for the domestic weight-loss drug market in 2026: In March next year, Novo Nordisk's blockbuster GLP-1 drug molecule semaglutide will see its core patent expire in China. Industry insiders predict that the supply of GLP-1 drugs in the future will far exceed the previous wave of PD-1 targeted drugs from pharmaceutical companies. With a large number of generic drugs coming to market, a price war for GLP-1 drugs is also expected to start in 2026. According to incomplete statistics, as of now, 8 domestic semaglutide drugs have received market approval, respectively from Huisheng Biology, Chengdu Betta, Shiyao Group, Hangzhou Zhongmei Huadong, Zhuhai Federal, Qilu, Lizhu, and Jiuyuan Genetics. (Yicai)